Susanne Malander
31 – 40 of 46
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
- Contribution to journal › Article
- 2015
-
Mark
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.
- Contribution to journal › Article
-
Mark
Ovarialcancer är på många sätt en heterogen sjukdom
- Contribution to journal › Article
- 2014
-
Mark
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
- Contribution to journal › Article
-
Mark
Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
- Contribution to journal › Article
-
Mark
Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome.
- Contribution to journal › Article
- 2011
-
Mark
Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors
- Contribution to journal › Article
- 2010
-
Mark
Genetic profiles distinguish different types of hereditary ovarian cancer.
- Contribution to journal › Article
- 2008
-
Mark
Response to letter of Escobar et al.
- Contribution to journal › Article
- 2007
-
Mark
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
- Contribution to journal › Article
